431 related articles for article (PubMed ID: 32929230)
21. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.
Zhong J; Gong Q; Goud A; Srinivasamaharaj S; Rajagopalan S
J Diabetes Res; 2015; 2015():606031. PubMed ID: 26075284
[TBL] [Abstract][Full Text] [Related]
23. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.
Chikata Y; Iwata H; Miyosawa K; Koike T; Yasuda H; Funamizu T; Doi S; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Isoda K; Okazaki S; Miyauchi K; Minamino T
Sci Rep; 2022 Mar; 12(1):5129. PubMed ID: 35332212
[TBL] [Abstract][Full Text] [Related]
25. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
Jones L; Jones AM
Pharmacol Res Perspect; 2022 Dec; 10(6):e01029. PubMed ID: 36468400
[TBL] [Abstract][Full Text] [Related]
26. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
27. Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?
Amouyal C; Levy P; Andreelli F; Hartemann A
Diabetes Metab; 2018 Feb; 44(1):95-96. PubMed ID: 28483292
[No Abstract] [Full Text] [Related]
28. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
McIntyre HF; Grant P
Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
[TBL] [Abstract][Full Text] [Related]
29. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
30. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
[TBL] [Abstract][Full Text] [Related]
31. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.
Del Prato S; Chilton R
Diabetes Obes Metab; 2018 Apr; 20(4):786-799. PubMed ID: 29171700
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
[TBL] [Abstract][Full Text] [Related]
34. The evolving place of incretin-based therapies in type 2 diabetes.
Gallwitz B
Pediatr Nephrol; 2010 Jul; 25(7):1207-17. PubMed ID: 20130920
[TBL] [Abstract][Full Text] [Related]
35. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
36. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
37. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
38. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
39. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
[TBL] [Abstract][Full Text] [Related]
40. The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?
Koufakis T; Zografou I; Doumas M; Kotsa K
Am J Cardiovasc Drugs; 2023 Nov; 23(6):601-608. PubMed ID: 37682449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
